We've been meandering around a tight price range for the last few weeks and now we pop 15% in two sessions. That seems unusual to me.
There is a lot of news that could come out any day:
Overseas joint ventures
Biomarker licensing info
Progress on activity test submission
Movement on changing AHA guidelines
Darapladib subgroup analysis
More analyst coverage
I read over the weekend, some more scientific analysis on the metabolism of Darapladib, see full article on:
Disposition and Metabolism of Darapladib, a Lipoprotein-associated Phospholipase A2 Inhibitor, in Humans
Clearly Glaxo is still busy with Darapladib and the data will continue to flow.
This is simply the January Effect. You had plenty of dimwittts(u know who you are) that loaded up at 2.12. They have all sold in the month of december for tax-losses, and now we are simply recovering without the added selling pressure.